Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Organon Foresees US Adalimumab Discounts Hitting 80%-90%
CEO Suggests Heavy Competition Will Lead To Steep Price Cuts By 2025-2026
Jan 11 2023
•
By
David Wallace
Humira biosimilar discounts could be substantial by 2025-2026 • Source: Shutterstock
More from Biosimilars
More from Products